Abstract:Currently, a considerable research effort is devoted to comparing LLMs to a group of human experts, where the term "expert" is often ill-defined or variable, at best, in a state of constantly updating LLM releases. Without proper safeguards in place, LLMs will threaten to cause harm to the established structure of safe delivery of patient care which has been carefully developed throughout history to keep the safety of the patient at the forefront. A key driver of LLM innovation is founded on community research efforts which, if continuing to operate under "humans versus LLMs" principles, will expedite this trend. Therefore, research efforts moving forward must focus on effectively characterizing the safe use of LLMs in clinical settings that persist across the rapid development of novel LLM models. In this communication, we demonstrate that rather than comparing LLMs to humans, there is a need to develop strategies enabling efficient work of humans with LLMs in an almost symbiotic manner.
Abstract:Cancer clinical trials often face challenges in recruitment and engagement due to a lack of participant-facing informational and educational resources. This study investigated the potential of Large Language Models (LLMs), specifically GPT4, in generating patient-friendly educational content from clinical trial informed consent forms. Using data from ClinicalTrials.gov, we employed zero-shot learning for creating trial summaries and one-shot learning for developing multiple-choice questions, evaluating their effectiveness through patient surveys and crowdsourced annotation. Results showed that GPT4-generated summaries were both readable and comprehensive, and may improve patients' understanding and interest in clinical trials. The multiple-choice questions demonstrated high accuracy and agreement with crowdsourced annotators. For both resource types, hallucinations were identified that require ongoing human oversight. The findings demonstrate the potential of LLMs "out-of-the-box" to support the generation of clinical trial education materials with minimal trial-specific engineering, but implementation with a human-in-the-loop is still needed to avoid misinformation risks.